Description
Bicalutamide is a non-steroidal androgen receptor inhibitor that binds competitively to androgen receptors, blocking the effects of androgens in target tissues. Prostate carcinoma, being androgen-sensitive, responds to treatments that reduce or inhibit androgen action. Casodex is used in combination with a luteinizing hormone-releasing hormone (LHRH) analog to treat Stage D2 metastatic carcinoma of the prostate.
Reviews
There are no reviews yet.